Fortress Biotech Inc. (NASDAQ:FBIO) rose 5.5% during trading on Friday . The company traded as high as $2.91 and last traded at $2.89, with a volume of 100,645 shares changing hands. The stock had previously closed at $2.74.

Separately, FBR & Co reissued an “outperform” rating and issued a $7.00 price objective on shares of Fortress Biotech in a research note on Wednesday, April 6th.

The company’s market cap is $140.21 million. The stock’s 50-day moving average is $2.74 and its 200 day moving average is $2.94.

Fortress Biotech (NASDAQ:FBIO) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter. Equities analysts forecast that Fortress Biotech Inc. will post ($0.30) EPS for the current year.

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.